Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration
about
Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMDAflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degenerationLipopolysaccharide Promotes Choroidal Neovascularization by Up-Regulation of CXCR4 and CXCR7 Expression in Choroid Endothelial Cell.Angiopoietin-like Protein 2 Is a Multistep Regulator of Inflammatory Neovascularization in a Murine Model of Age-related Macular Degeneration.One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement.Functional Visual Acuity in Age-Related Macular DegenerationPredicting vision gains with anti-VEGF therapy in neovascular age-related macular degeneration patients by using low-luminance vision.Genome editing abrogates angiogenesis in vivo.Elevated angiopoietin 2 in aqueous of patients with neovascular age related macular degeneration correlates with disease severity at presentation.Choose the right treatment for the right patientsNon-responsiveness to intravitreal aflibercept treatment in neovascular age-related macular degeneration: implications of serous pigment epithelial detachment.Age-related macular degeneration: using morphological predictors to modify current treatment protocols.Ranibizumab for vascularized pigment epithelial detachment: 1-year anatomic and functional results.Benefits of aflibercept treatment for age-related macular degeneration patients with good best-corrected visual acuity at baseline.Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan.Baseline Predictors of Visual Acuity Outcome in Patients with Wet Age-Related Macular Degeneration.
P2860
Q26748731-A06AE0F5-F7B8-427B-89D0-F10C1696263AQ26771522-F1F85922-4A66-4622-85CF-FCE992D89B37Q35750353-41343645-456F-4FEF-B7BE-F8600C9113BCQ35912788-5C2D68E6-7CEA-49D4-A19F-D6483CADD065Q36955686-35589232-E3ED-4177-9D67-CEDCBA6FB2ABQ36961801-FB29C962-F02A-4D2A-A456-5FF7B891E69BQ37156382-3A33E038-8655-4FEB-B311-A83570087AEEQ40109925-F22E6BE5-7805-481C-B95B-AC3E74554E85Q41950821-F8AFDFE0-DC40-4941-B454-7D8E3566B4CAQ42359933-90772678-768E-4967-8F46-DE96EA792292Q42426609-17DD2871-646E-42D6-B83C-E30053FA2E7AQ46805189-A01B82DB-9234-4291-B717-3466AAA222F8Q47616707-C55D3E30-A814-4C88-85BA-0246D3C15DAAQ48293183-0FC82D64-7E4E-4F7C-BD1D-ECDAE5157F2DQ55009931-FB331632-EE2C-44AF-913A-B4CBF7A96AA3Q55289375-46751EAE-2C97-4087-97C5-470EAB3E5ACE
P2860
Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Predictive factors for non-res ...... e-related macular degeneration
@ast
Predictive factors for non-res ...... e-related macular degeneration
@en
Predictive factors for non-res ...... e-related macular degeneration
@nl
type
label
Predictive factors for non-res ...... e-related macular degeneration
@ast
Predictive factors for non-res ...... e-related macular degeneration
@en
Predictive factors for non-res ...... e-related macular degeneration
@nl
prefLabel
Predictive factors for non-res ...... e-related macular degeneration
@ast
Predictive factors for non-res ...... e-related macular degeneration
@en
Predictive factors for non-res ...... e-related macular degeneration
@nl
P2093
P2860
P1476
Predictive factors for non-res ...... e-related macular degeneration
@en
P2093
Hajime Shinoda
Hiroshi Mochimaru
Kanako Izumi-Nagai
Kazuo Tsubota
Kenya Yuki
Mariko Sasaki
Misa Suzuki
Norihiro Nagai
Takashi Koto
Yoko Ozawa
P2860
P304
P356
10.1136/BJOPHTHALMOL-2013-304670
P407
P577
2014-04-07T00:00:00Z